In­di­an phar­ma re­ceives FDA warn­ing let­ter for bare­foot em­ploy­ees and gen­er­al 'dis­re­pair'

Fol­low­ing a ma­jor re­call of eye drop prod­ucts, In­dia-based phar­ma Kil­itch Health­care re­ceived a warn­ing let­ter from the FDA not­ing that mul­ti­ple em­ploy­ees were work­ing bare­foot in des­ig­nat­ed clean rooms, and in some cas­es, sam­ple re­sults were fab­ri­cat­ed.

The warn­ing let­ter, pub­lished on Tues­day and sent to Kil­itch on March 28, fol­lows an Oc­to­ber 2023 in­spec­tion at Kil­itch’s fa­cil­i­ty in Mum­bai.

The fa­cil­i­ty was in a state of “dis­re­pair,” ac­cord­ing to the warn­ing let­ter, with the FDA in­spec­tors not­ing peel­ing paint, stains and residues.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER